Bromide

Bromide

SCHEMBL1502787

Br.Cc1ccc(N)c(C)c1C

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 9/20 0.48
TSHR P16473 5/20 0.48
PIK3CA P42336 1/20 0.48
ALDH1A1 P00352 6/20 0.42
TDP1 Q9NUW8 6/20 0.42
POLB P06746 1/20 0.42
CASP1 P29466 1/20 0.42
NOS3 P29474 2/20 0.39
NOS2 P35228 2/20 0.39
TP53 P04637 1/20 0.38
THRB P10828 1/20 0.38
ALOX15 P16050 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CD44 P16070 1/20 0.36
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL4593968 1.00 CYP3A4 (0.48) CYP3A4TSHRPIK3CAALDH1A1TDP1
Bromide SCHEMBL11815034 1.00 CYP3A4 (0.48) CYP3A4TSHRPIK3CAALDH1A1TDP1
Bromide SCHEMBL128888 1.00 CYP3A4 (0.48) CYP3A4TSHRPIK3CAALDH1A1TDP1
SCHEMBL33509 0.97 CYP3A4 (0.50) CYP3A4TSHRPIK3CAALDH1A1TDP1
Water SCHEMBL35583 0.94 CYP3A4 (0.48) CYP3A4TSHRPIK3CAALDH1A1TDP1
Iodide SCHEMBL1157672 0.94 CYP3A4 (0.48) CYP3A4TSHRPIK3CAALDH1A1TDP1
Fluoride SCHEMBL1502751 0.94 CYP3A4 (0.48) CYP3A4TSHRPIK3CAALDH1A1TDP1
Water SCHEMBL9259705 0.94 CYP3A4 (0.48) CYP3A4TSHRPIK3CAALDH1A1TDP1
Hydrochloric Acid SCHEMBL553599 0.94 CYP3A4 (0.48) CYP3A4TSHRPIK3CAALDH1A1TDP1
SCHEMBL15346025 0.94 CYP3A4 (0.48) CYP3A4TSHRPIK3CAALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 497 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120049017-A Org/ZnSO4Electrolyte, preparation method thereof and application of electrolyte in secondary battery 同济大学 2025-05-27 CN claimed
US-20240279551-A1 LIQUID CRYSTAL EMULSIONS AND USES THEREOF CORNELL UNIVERSITY 2024-08-22 US claimed
WO-2023283010-A2 LIQUID CRYSTAL EMULSIONS AND USES THEREOF CORNELL UNIVERSITY (US) 2023-01-12 WO claimed
WO-2020159007-A1 METHOD FOR PREPARING ACYLOXYBENZENESULFONATE COMPOUND 주식회사 비제이바이오켐 2020-08-06 WO claimed
US-20110224458-A1 PREPARATION OF METHIONINE OR SELENOMETHIONINE FROM HOMOSERINE VIA A 4-SUBSTITUTED 2-AMINOBUTANOIC ACID INTERMEDIATE NOVUS INTERNATIONAL INC. (US) 2011-09-15 US claimed
US-7635662-B2 Compound for color-producing composition, and recording material CHEMIPRO KASEI KAISHA, LTD. (JP) 2009-12-22 US claimed
EP-0821268-B1 An emulsion for a photothermographic material, a production process for the photothermographic material and a recording process therefor AGFA GEVAERT (BE) 2004-04-07 EP claimed
US-6383725-B2 ORGANIC SILVER SALT, PHOTOSENSITIVE SILVER HALIDE AND CATALYST AGFA-GEVAERT (BE) 2002-05-07 US claimed
US-20010028996-A1 Emulsion for a photothermographic material, a production process for the thermographic material and a recording process therefor AGFA GEVAERT 2001-10-11 US claimed
US-6187516-B1 LIGHT-INSENSITIVE ORGANIC SILVER SALT, PHOTOSENSITIVE SILVER HALIDE; SILVER SALT; BINDER; TETRAMETHYLAMMONIUM CHLORIDE PERBROMIDE, TRIMETHYLPHENYLAMMONIUM BROMIDE PERBROMIDE OR TETRAMETHYLAMMONIUM BROMIDE AGFA-GEVAERT (BE) 2001-02-13 US claimed
EP-0821268-A1 An emulsion for a photothermographic material, a production process for the photothermographic material and a recording process therefor AGFA-GEVAERT N.V. (BE) 1998-01-28 EP claimed
EP-0010843-B1 METHOD OF MAKING 5,6-DIHYDRO-2-METHYL-N-PHENYL-1,4-OXATHIIN-3-CARBOXAMIDE UNIROYAL LTD. (CA) 1983-11-09 EP claimed
US-4281198-A REACTING TRIMETHYLANILINIUM HALIDE WITH HYDRAZINE OR MONOMETHYLHYDRAZINE JAPAN HYDRAZINE CO., INC. (JP) 1981-07-28 US claimed
EP-0010843-A1 Method of making 5,6-dihydro-2-methyl-N-phenyl-1,4-oxathiin-3-carboxamide UNIROYAL LTD. (CA) 1980-05-14 EP claimed
US-4182716-A Method of making 5,6-dihydro-2-methyl-N-phenyl-1,4-oxathiin-3-carboxamide UNIROYAL, LTD. (CA) 1980-01-08 US claimed
US-20260118767-A1 REVERSE PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2026-04-30 US disclosed
US-12606513-B2 Formate production method, formic acid production method, and antifreezing agent production method NITTO DENKO CORPORATION (JP) 2026-04-21 US disclosed
US-4008219-A CNS ANALGESIC, ANTITUSSIVE, SEDATIVE NIHON IYAKUHIN KOGYO CO., LTD. (JA) 1977-02-15 US disclosed
US-4003749-A Heat-developable light-sensitive materials using the reaction product of a organic silver salt an a N-halo-oxazolidinone FUJI PHOTO FILM CO., LTD. (JA) 1977-01-18 US disclosed
US-4002479-A ORGANIC SILVER SALT, SILVER HALIDE, AND A REDUCING AGENT FUJI PHOTO FILM CO., LTD. (JA) 1977-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12606513-B2 Formate production method, formic acid production method, and antifreezing agent production method CA2, TAF5, HACL2 CYP3A4 1600/4885TSHR 2160/4885PIK3CA 3911/4885
US-20260118767-A1 REVERSE PATTERNING PROCESS EFNA1, EPHA4, ETV6 CYP3A4 3527/4885TSHR 770/4885PIK3CA 422/4885
US-20110224458-A1 PREPARATION OF METHIONINE OR SELENOMETHIONINE FROM HOMOSERINE VIA A 4-SUBSTITUTED 2-AMINOBUTANOIC ACID INTERMEDIATE MTR, CBS, ABAT CYP3A4 646/4885TSHR 2605/4885PIK3CA 3133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.